Taken together, sorafenib suppressed various intracellular signaling pathways in thyroid carcinoma cells treated in vitro, including VEGFRs, PDGFRs as well as various MAP kinase- and AKT-dependent pathways. This evidence concerns the gene AKT1 and thyroid gland carcinoma.